Literature DB >> 11060754

Tetracyclines for the treatment of rheumatoid arthritis.

G S Alarcón1.   

Abstract

In this review the rationale for the possible beneficial effect of tetracycline derivatives for the treatment of rheumatoid arthritis is discussed. Early studies (Sanchez, Skinner et al. and Brown et al. ) and the two open trials of the 1980s are briefly discussed. The three double-blind studies conducted in the 1990s (Kloppenburg et al. , The Netherlands; the MIRA trial, USA and the O'Dell et al., USA) are described in detail. The baseline clinical and demographic data for these patients, as well as the efficacy and toxicity data are described in the text and summarised in tables. The long-term data of the O'Dell et al.'s trial is described. Finally, side effects not observed during the conduct of these trials, but reported to occur in other patients, for example those receiving minocycline for the treatment of acne, are also listed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060754     DOI: 10.1517/13543784.9.7.1491

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  4 in total

1.  Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells.

Authors:  Gregory L Szeto; Angela K Brice; Hung-Chih Yang; Sheila A Barber; Robert F Siliciano; Janice E Clements
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

Review 2.  Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.

Authors:  Alejandro Díaz-Borjón
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 3.  Antibiotics for the treatment of rheumatoid arthritis.

Authors:  Mesut Ogrendik
Journal:  Int J Gen Med       Date:  2013-12-27

Review 4.  Hypoxia-dependent drivers of melanoma progression.

Authors:  Simona D'Aguanno; Fabiana Mallone; Donatella Del Bufalo; Antonietta Moramarco; Marco Marenco
Journal:  J Exp Clin Cancer Res       Date:  2021-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.